CHARITY: Cha gas car diomyopathy bi soprolol int ervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]

Quiros, Franklin R; Morillo, Carlos A.; Casas, Juan P.; Cubillos, Luz A; Silva, Federico A.

doi:10.1186/1745-6215-7-21

Cited by 21 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…β-Blockers (carvedilol, metoprolol or bisoprolol), another cornerstone in the treatment of HF as a result of other aetiologies, are usually recommended as routine therapy for asymptomatic patients with a LV EF <40%, especially if they do not have pronounced bradycardia or hypotension, as well as for patients with manifest HF. However, the ability of β-blockers to reduce mortality in patients with Chagas cardiomyopathy remains to be determined 63. Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload.…”

Section: Tertiary Prevention Of Chagas’ Diseasementioning

confidence: 99%

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

Rassi¹,

Dias²,

Marin-Neto³

2008

Heart

123

106

View full text Add to dashboard Cite

A century after its discovery, Chagas' disease still represents a major public health challenge in Latin America. Moreover, because of growing population movements, an increasing number of cases of imported Chagas' disease have now been detected in non-endemic areas, such as North America and some European countries. This parasitic zoonosis, caused by Trypanosoma cruzi, is transmitted to humans by infected Triatominae insects, or occasionally by non-vectorial mechanisms, such as blood transfusion, mother to fetus, or oral ingestion of materials contaminated with parasites. Following the acute phase of the infection, untreated individuals enter a chronic phase that is initially asymptomatic or clinically unapparent. Usually, a few decades later, 40-50% of patients develop progressive cardiomyopathy and/or motility disturbances of the oesophagus and colon. In the last decades several interventions targeting primary, secondary and tertiary prevention of Chagas' disease have been attempted. While control of both vectorial and blood transfusion transmission of T cruzi (primary prevention) has been successful in many regions of Latin America, early detection and aetiological treatment of asymptomatic subjects with Chagas' disease (secondary prevention) have been largely underutilised. At the same time, in patients with established chronic disease, several pharmacological and non-pharmacological interventions are currently available and have been increasingly used with the intention of preventing or delaying complications of the disease (tertiary prevention). In this review we discuss in detail each of these issues.

show abstract

Section: Tertiary Prevention Of Chagas’ Diseasementioning

confidence: 99%

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

Rassi¹,

Dias²,

Marin-Neto³

2008

Heart

123

106

View full text Add to dashboard Cite

show abstract

“…Currently, the management of the chronic chagasic patient with cardiomyopathy is being carried out similarly to patients with cardiopathies of other etiologies, with the use of betablockers having been validated in these patients 68 .…”

Section: Discussionmentioning

confidence: 99%

Envolvimento de auto-anticorpos na fisiopatologia da Doença de Chagas

Medei¹,

Nascimento

Pedrosa

et al. 2008

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

Summary Chagas’ disease is a serious health problem in Latin America. Between 25 to 30% of the infected patients develop the chronic form of the disease, with progressive myocardial damage and often, sudden death. Adrenergic or cholinergic antibodies with G-protein coupled membrane receptor activity may be present in the sera of these patients. The present study discusses the etiology and the contribution of antibodies to the physiopathology of Chagas’ disease.

show abstract

“…Beta-adrenergic blockers (carvedilol, bisoprolol, or metoprolol) are suggested in association with ACEI and ARB due to autonomous nervous system involvement in CCC and the production of antibodies against β-1 adrenergic and M-2 muscarinic receptors [25,73,79,83]. Limited reports address the efficacy of this therapeutic class to treat Chagas patients with ventricular dysfunction [86,[92][93][94][95][96]. Beta blockers have been avoided because of the presence of frequent bradycardia; therefore these drugs are not indicated for patients with bradycardia ≤50 bpm or AV conduction disorders (PR > 280 ms) [25,73,79,83].…”

Section: Chronic Chagas Cardiomyopathy (Ccc)mentioning

confidence: 99%

Efficacy and Safety of Chagas Disease Drug Therapy and Treatment Perspectives

Kawaguchi¹,

Cerqueira²,

MillanFachi³

et al. 2018

Chagas Disease - Basic Investigations and Challenges

View full text Add to dashboard Cite

Chagas disease, also known as American trypanosomiasis, is a neglected disease caused by the protozoan parasite Trypanosoma cruzi. The disease affects about 6-7 million people worldwide, mostly in Latin America. Although Chagas disease was discovered more than 100 years ago, and the first treatments over 40, only 2 drugs were used to treat this pathology, it is still considered one of the neglected diseases. In this chapter, the subjects related to conventional etiological therapies, benznidazole and nifurtimox, such as the drug, the mechanism of action, the therapy schedule for treatment, efficacy and safety and their adverse effects will be discussed. Additionally, it will address alternative therapies of comorbidities related to the progression of Chagas' disease in patients with chronic disease, such as heart disease and dysfunction of the digestive system. Finally, novel pharmacological strategies and their related compounds will be reviewed accounting for their progression in pharmacological studies and their success rate.

show abstract

CHARITY: Cha gas car diomyopathy bi soprolol int ervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]

Cited by 21 publications

References 21 publications

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

Envolvimento de auto-anticorpos na fisiopatologia da Doença de Chagas

Efficacy and Safety of Chagas Disease Drug Therapy and Treatment Perspectives

Contact Info

Product

Resources

About